Sofosbuvir

Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. (In Vitro) :When cathepsin A (CatA) is incubated with PSI-7977 or Sofosbuvir (PSI-7977) for 150 min, ~18-fold more PSI-352707 is formed when Sofosbuvir (PSI-7977) is the substrate compared with PSI-7976. Moreover, the catalytic efficiency for Sofosbuvir (PSI-7977) with CatA is ~30-fold higher than that for PSI-7976. The genotype coverage of Sofosbuvir (PSI-7977) by using GT 1b (Con1) -, 1a (H77) -, and 2a (JFH-1) -derived replicons and GT 1b chimeric replicons containing the NS5B region from the J6 GT 2a isolate and from GT 2b and GT 3a patient isolates is evaluated, Sofosbuvir (PSI-7977) inhibits the replication of these replicons with similar EC50s (between 16 and 48 nM), and is especially active against the chimeric replicon containing the J6 NS5B (EC50=4.7 nM) . Sofosbuvir (PSI-7977) inhibits clone A (GT 1b) wild-type and S282T replicons with EC90 values of 0.42 and 7.8 μM, respectively. In the clone A replicon assay, Sofosbuvir (PSI-7977) produces anti-HCV activity with EC90 values 0.42 μM.

Product Specifications

CAS Number

1190307-88-0

Product Name Alternative

PSI-7977, GS-7977

Field of Research

Pharmacology & Drug Discovery

Purity

>98% (HPLC)

Solubility

DMSO:100 mg/mL warmed (188.87 mM) Ethanol:100 mg/mL (188.87 mM) Water:11 mg/mL warmed (20.77 mM)

Smiles

C[C@@H] (C (=O) OC (C) C) NP (=O) (OC[C@@H]1[C@H] ([C@@] ([C@@H] (O1) N2C=CC (=O) NC2=O) (C) F) O) OC3=CC=CC=C3

Molecular Formula

C22H29FN3O9P

Molecular Weight

529.45

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

(2S) -isopropyl 2- (((((2R,3R,4R,5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -yl) -4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate